Open Access

Circulating microRNA profile predicts disease progression in patients receiving second-line treatment of lapatinib and capecitabine for metastatic pancreatic cancer

  • Authors:
    • Xuefei Tian
    • Narayan Shivapurkar
    • Zheng Wu
    • Jimmy J. Hwang
    • Michael J. Pishvaian
    • Louis M. Weiner
    • Lisa Ley
    • Dan Zhou
    • Xiuling Zhi
    • Anton Wellstein
    • John L. Marshall
    • Aiwu Ruth He
  • View Affiliations

  • Published online on: January 13, 2016     https://doi.org/10.3892/ol.2016.4101
  • Pages: 1645-1650
  • Copyright: © Tian et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Patients exhibiting pancreatic cancer possess poor rates of survival. Therefore, the identification of a biomarker that can be measured non-invasively and be used to predict patient outcomes is required for the successful treatment of pancreatic cancer. The present study evaluated serum microRNA (miRNA/miR) profiles in patients exhibiting pancreatic cancer, who were treated with lapatinib and capecitabine in a phase II trial. Serum samples were collected for the measurement of a panel of miRNAs (miR‑21, miR‑210, miR‑221 and miR‑7) associated with the epidermal growth factor receptor (EGFR)1 and human epidermal growth factor receptor (HER)2 pathways. Preclinically, human pancreatic cancer PANC‑1, MIA PaCa‑2 and BXCP‑3 cell lines were utilized for miRNA and drug resistance studies. In total, 6/17 patients treated experienced disease progression following 2 cycles of treatment [non‑responders (NRS)], while another 6/17 patients exhibited a stable disease state and received >4 cycles of treatment [responders (RS); range, 4‑22 cycles]. Five patients withdrew from the study due to severe toxicity or mortality. The mean overall survival time was 6.5 vs. 10.4 months for NRS and RS, respectively. Significant upregulation of serum miRNAs at earlier time points (3‑6 weeks) was observed in NRS. miRNA levels increased with cancer progression, and lapatinib and 5‑fluorouracil (5‑FU; the active form of capecitabine) treatment increased the miRNA levels (specifically miR‑210 and miR‑221) in the treatment‑resistant pancreatic cancer PANC‑1 and MIA PaCa‑2 cell lines. However, lapatinib and 5‑FU treatment did not increase the miRNA levels in the treatment‑sensitive BXPC‑3 cell line. Inhibition of miR‑221 increased the sensitivity of the PANC‑1 cells to treatment. In conclusion, an increase in specific serum miRNAs was associated with resistance to lapatinib and capecitabine treatment. Additional investigation is required with regard to the application of the miRNA panel investigated in the present study as a potential predictor of patient responses to anti-EGFR/HER2 treatment.
View Figures
View References

Related Articles

Journal Cover

March-2016
Volume 11 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Tian X, Shivapurkar N, Wu Z, Hwang JJ, Pishvaian MJ, Weiner LM, Ley L, Zhou D, Zhi X, Wellstein A, Wellstein A, et al: Circulating microRNA profile predicts disease progression in patients receiving second-line treatment of lapatinib and capecitabine for metastatic pancreatic cancer. Oncol Lett 11: 1645-1650, 2016
APA
Tian, X., Shivapurkar, N., Wu, Z., Hwang, J.J., Pishvaian, M.J., Weiner, L.M. ... He, A.R. (2016). Circulating microRNA profile predicts disease progression in patients receiving second-line treatment of lapatinib and capecitabine for metastatic pancreatic cancer. Oncology Letters, 11, 1645-1650. https://doi.org/10.3892/ol.2016.4101
MLA
Tian, X., Shivapurkar, N., Wu, Z., Hwang, J. J., Pishvaian, M. J., Weiner, L. M., Ley, L., Zhou, D., Zhi, X., Wellstein, A., Marshall, J. L., He, A. R."Circulating microRNA profile predicts disease progression in patients receiving second-line treatment of lapatinib and capecitabine for metastatic pancreatic cancer". Oncology Letters 11.3 (2016): 1645-1650.
Chicago
Tian, X., Shivapurkar, N., Wu, Z., Hwang, J. J., Pishvaian, M. J., Weiner, L. M., Ley, L., Zhou, D., Zhi, X., Wellstein, A., Marshall, J. L., He, A. R."Circulating microRNA profile predicts disease progression in patients receiving second-line treatment of lapatinib and capecitabine for metastatic pancreatic cancer". Oncology Letters 11, no. 3 (2016): 1645-1650. https://doi.org/10.3892/ol.2016.4101